←
Cancer Links5,739 posts
Cancer Links avatar

Cancer Links

@LinksCancer

🧬Sharing #CancerResearch, news, and breakthroughs. Links & Retweets 📰✨ #CancerAwareness #CancerSupport 💪💜

◷ Joined June 2023▧ 12 Photos and videos
Stephen V Liu, MD avatar
⟳ Cancer Links retweeted
Stephen V Liu, MD@StephenVLiu·Jun 1

Dr. Tina Cascone outlines rationale & science behind neoadjuvant and perioperative immunotherapy for early stage NSCLC at #ASCO26. How do we isolate the value of the adjuvant component after pCR or non-pCR? How do we best escalate non-pCR? ADC? Vaccine? Insightful discussion.

Post attachmentPost attachmentPost attachmentPost attachment
Stephen V Liu, MD avatar
⟳ Cancer Links retweeted
Stephen V Liu, MD@StephenVLiu·Jun 1

Dr. @g_mountzios #ASCO26 presents CNS outcomes with 2L tarlatamab in DeLLphi-304. Improved time to CNS progression overall (HR 0.54). In pts with brain nets, tarlatamab vs chemo CNS CR rate 15% vs 5% with DCR 78% vs 71% and time to CBS progression 6.5m vs 4.2m, HR 0.40

Post attachmentPost attachmentPost attachmentPost attachment
Stephen V Liu, MD avatar
⟳ Cancer Links retweeted
Stephen V Liu, MD@StephenVLiu·Jun 2

Dr. @LuisPaz_Ares: biomarkers from phase III IMforte trial of maintenance lurbinectedin in SCLC #ASCO26. PFS & OS benefit of maintenance lurbinectedin seen across molecular subtypes and independent of SLFN11 expression. Suggestion that lurbi may overcome TAM-mediated resistance.

Post attachmentPost attachmentPost attachmentPost attachment
Aya Mohamed | MSc, MD 🎗 avatar
⟳ Cancer Links retweeted
Aya Mohamed | MSc, MD 🎗@Dr_Oncologista·Jun 1

#SCLC Update 🚨 (First-in-Human ABBV-706):🫁 SEZ6-targeted ADC delivers a striking signal in R/R disease with ORR 82% in 2L and deep disease control even in chemotherapy-refractory cohorts (CTFI <30d), with early OS trend 14.3 mo—redefining the ADC landscape in SCLC. @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment
Alfredo Addeo MD avatar
⟳ Cancer Links retweeted
Alfredo Addeo MD@Alfdoc2·May 31

One of the most awaited presentations( at least by me) #ASCO26: HARMONi-6 shows that ivonescimab + chemo significantly improves OS Vs tislelizumab + chemo in first-line advanced Sq #NSCLC (HR 0.66). A positive phase III study with a clinically meaningful OS benefit and simultaneous publication in @TheLancet: thelancet.com/journals/lance… Caveat: this was a study conducted entirely in China. How these data will translate globally remains an important question? Let’s see what HARMONI 3 will show

Post attachmentPost attachmentPost attachmentPost attachment
Jun Gong, MD avatar
⟳ Cancer Links retweeted
Jun Gong, MD@jgong15·Jun 1

Dr. Zhao PhII study of ZG006 (tri-specific T-cell engager DLL3/CD3) in refractory #NEC (1 prior line) ➡️ ORR 57.3%, median DoR 11.76 mos, median PFS 7.06 mos, median OS NR in 30 mg cohort if DLL3 tumor cell staining >50%, 68.8% G>3 TRAEs, no G5 events in 30 mg #ASCO26 @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment
Jun Gong, MD avatar
⟳ Cancer Links retweeted
Jun Gong, MD@jgong15·Jun 1

Dr. Oh Asian-based PhIII ATTRACTION-6 trial of platinum-chemo +/- nivo/ipi (1 mg/kg Q6W) in #1L HER2- met GC/GEJC (55% CPS<5) ➡️ no sig diff in median OS 15.7 vs 15.8 mos or PFS 8.9 vs 7.7 mos in ITT, 3 mo OS ⬆️ in CPS>5 & ORR 57.9 vs 38.5% in favor of chemoIO #ASCO26 @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment
Nicholas Hornstein avatar
⟳ Cancer Links retweeted
Nicholas Hornstein@GIMedOnc·May 31

#ASCO26 This one is special. This is the hottest paper of 2026 and potentially in the history of pancreatic cancer. Let’s dive in. RASolute 302: Daraxonrasib vs investigator’s choice chemotherapy in previously treated metastatic pancreatic cancer Abstract LBA5 (soon!) Presentation: May 31, 2026, 3:21-3:33 PM CDT For decades, pancreatic cancer has been where good ideas go to die. We have optimized chemotherapy. We have sequenced chemotherapy. We have celebrated modest gains. But the central driver of PDAC has always been sitting there in plain sight: RAS. More than 90% of pancreatic cancers have oncogenic RAS mutations, and until recently, we had essentially nothing direct to do about it. Daraxonrasib is an oral RAS(ON) multiselective inhibitor targeting the active GTP-bound state of mutant and wild-type RAS. And in RASolute 302, it delivered. Quick hits: 📌 Phase 3 international randomized trial 500 patients with previously treated mPDAC Daraxonrasib vs investigator’s choice chemotherapy 🧬 RAS G12 population 91.8% of patients had RAS G12 mutations 📈 OS in RAS G12 population 13.2 vs 6.6 months HR 0.40 P<0.001 📈 OS in overall population 13.2 vs 6.7 months HR 0.40 P<0.001 📊 PFS in RAS G12 population 7.3 vs 3.5 months HR 0.45 P<0.001 📊 PFS in overall population 7.2 vs 3.6 months HR 0.49 P<0.001 🔥 12-month OS Overall population: 53.2% vs 17.3% ⚠️ Toxicity matters, but this was not just more efficacy for more toxicity Grade ≥3 AEs: 61.8% vs 69.6% TRAEs leading to discontinuation: 1.2% vs 11.2% This is the kind of survival curve we almost never get to see in pancreatic cancer. This validates RAS(ON) inhibition in the most RAS-addicted major cancer. It takes a target we have talked about for decades and turns it into a clinically meaningful survival benefit in a randomized phase 3 trial. The next questions come fast: 1L combinations, maintenance, perioperative disease, sequencing, resistance, toxicity management, and whether this becomes a new backbone. RAS is here, and it couldn’t have come sooner. nejm.org/doi/full/10.1056/NE… @TheGutonclab @UGrewalMD @TimothyJBrownMD @OncoAlert @Onco_Nexus @ASCO @NazliDizman @LauraAlderMD @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @DrSAHaddad @jgong15 @iandresmeraz @SakditadMD @RamilaShilpakar @RohitBanwar @lungoncdoc

Post attachment
Dee Sparacio avatar
⟳ Cancer Links retweeted
Dee Sparacio@womenofteal·Jun 1

#ASCO26 Watched On Demand "Elevating the Patient Voice..." Thanks @stage4kelly for being our voice! Yes, advocates are @ASCO members. We are ready to be involved.Yes, PROs should be included in every trial. Yes, QOL measures should be co-primary end pts. #gyncsm

Post attachmentPost attachmentPost attachmentPost attachment